[They] evaluated data from the Testosterone Effects on Atherosclerosis in Aging Men trial on 134 men (mean age, 66.7 years; mean BMI, 28.1 kg/m[SUP]2[/SUP]) with low or low-normal testosterone (total testosterone, 100-400 ng/dL; free testosterone, < 50 pg/mL) without diabetes randomly assigned to placebo (n = 60) or testosterone (n = 74). Participants had a baseline and at least one post-randomization assessment of insulin sensitivity by an octreotide suppression test. Researchers sought to determine the effects of long-term (3 years) testosterone administration in insulin sensitivity.
At 36 months, mean on-treatment testosterone concentrations increased from 330 ng/dL at baseline to 477.1 ng/dL in the testosterone group, whereas they did not change significantly in the placebo group.
Steady-state plasma glucose increased during the 36 months in the placebo group (P = .03), whereas there were no significant differences observed in the testosterone group
